

A DIFFERENT WAY TO RECEIVE TREATMENT

SARCLISA ESCENA
is the only multiple myeloma therapy for adults available with an on-body injector

What is SARCLISA ESCENA?

SARCLISA ESCENA is a prescription medicine used in combination with:

- The medicines pomalidomide and dexamethasone, to treat adults who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
- The medicines carfilzomib and dexamethasone, to treat adults with multiple myeloma who have already received 1 to 3 lines of treatment, and they did not work or are no longer working.
- The medicines bortezomib, lenalidomide, and dexamethasone, to treat adults with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant).

It is not known if SARCLISA ESCENA is safe and effective in children.

Important Safety Information

Do not receive SARCLISA ESCENA if you have a severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA ESCENA (see the list of ingredients in the full Prescribing Information).

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

FOR USE WITH CirCLIQ™ On-Body Delivery System

Deciding with your doctor whether SARCLISA ESCENA™ may be an option for you

An informed decision starts with the right information

Talking with your doctor about your options is an important step in your multiple myeloma treatment journey. If you're considering treatment with SARCLISA ESCENA, the questions below can help you start the conversation with your doctor.

Questions you may want to ask your doctor about SARCLISA ESCENA

- Is SARCLISA ESCENA the right option for me?
- How will I know SARCLISA ESCENA is working?
- What are the possible side effects of treatment with SARCLISA ESCENA?
- Are there support options to help me or my loved one afford treatment with SARCLISA ESCENA?
- Why is SARCLISA ESCENA taken with other medicines?

Bring these questions to your next appointment to help guide a conversation with your doctor about SARCLISA ESCENA.

Important Safety Information (cont'd)

Before you receive SARCLISA ESCENA, tell your healthcare provider about all of your medical conditions, including if you:

- Have an infection.
- Have heart problems, if your healthcare provider prescribes SARCLISA ESCENA in combination with carfilzomib and dexamethasone for you.
- Have had shingles (herpes zoster).
- Are pregnant or plan to become pregnant. SARCLISA ESCENA can harm your unborn baby.

  Females who are able to become pregnant:

  – Your healthcare provider will check for pregnancy before you start treatment with SARCLISA ESCENA.

  – Use an effective birth control (contraception) during treatment and for 7 months after your last dose of SARCLISA ESCENA. Talk to your healthcare provider about birth control methods that you can use during this time.

  – Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with SARCLISA ESCENA.

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

What you'll find in this guide

About multiple myeloma 4

How SARCLISA ESCENA works 7

Introducing SARCLISA ESCENA with CirCLIQ 8

SARCLISA ESCENA clinical trials 10

Possible side effects of SARCLISA ESCENA 14

Preparing for and what to expect during your treatment 17

Frequently asked questions 19

Treatment with SARCLISA ESCENA with CirCLIQ 20

Access and support for SARCLISA ESCENA 22

Find helpful resources 25

Glossary of terms 26

Important Safety Information 26

Some terms and abbreviations in this guide related to multiple myeloma and its treatment may be unfamiliar. **If anything is unclear, you can find helpful explanations in the glossary on page 26.**

SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

FOR USE WITH CirCLIQ™ On-Body Delivery System

What is multiple myeloma?

Multiple myeloma is a type of cancer that affects the blood

Multiple myeloma impacts how your body makes blood cells and fights infections.

- Multiple myeloma damages types of white blood cells called plasma cells. Plasma cells are found in the bone marrow. Healthy plasma cells make antibodies that help the body fight infections. In multiple myeloma, healthy plasma cells sometimes turn into myeloma cells. Myeloma cells grow and multiply much more than normal. They also begin producing harmful antibodies called monoclonal proteins, or M-proteins
- These multiple myeloma cells and M-proteins can damage your bones and other organs, such as the kidneys

Your care team may use different words to describe or define your condition:

- Newly diagnosed multiple myeloma, or NDMM, is when you have not been treated before
- Relapsed is when multiple myeloma returns after treatment
- Refractory is when multiple myeloma is not responding to treatment

Important Safety Information (cont'd)

Before you receive SARCLISA ESCENA, tell your healthcare provider about all of your medical conditions, including if you: (cont'd)

Females and males: Before receiving SARCLISA ESCENA in combination with either pomalidomide or lenalidomide, females and males must agree to the instructions in the pomalidomide or lenalidomide REMS programs. The pomalidomide and lenalidomide REMS programs have specific requirements about birth control, pregnancy testing, blood donation, and sperm donation that you need to know. Talk to your healthcare provider to learn more about pomalidomide or lenalidomide.

- Are breastfeeding or plan to breastfeed. It is not known if SARCLISA ESCENA passes into your breast milk. Do not breastfeed during treatment with SARCLISA ESCENA and for 7 months after your last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

How is multiple myeloma treated?

Treatments may help control multiple myeloma by reducing the number of cancerous cells in the body

Right now, there is no cure for multiple myeloma. But treatments have improved over the years, and people with multiple myeloma are now living longer than before. There are different treatment options available:

TARGETED THERAPY	IMMUNOTHERAPY	CHEMOTHERAPY	CORTICOSTEROIDS
focuses on specific functions within cancer cells and blocks them	uses the body's own immune system to kill cancer cells	kills cancer cells directly	control inflammation

BONE MARROW TRANSPLANT	RADIATION THERAPY	CAR-T CELL THERAPY
replaces damaged bone marrow with healthy bone marrow	uses high-powered energy beams to kill cancer cells	trains your body's white blood cells to find and kill cancer cells. CAR-T cell therapy stands for chimeric antigen receptor T-cell therapy

How might combining different treatment options work for you?

Many doctors combine different medications to treat multiple myeloma. Each medication may help fight the cancer and/or symptoms in different ways.

Your doctor will look at several factors before choosing your treatment regimen. These include your kidney function, age, and overall health. Together, these factors help determine which treatment plan may be the right fit for you. It is common for multiple myeloma treatment plans to include 3 or more medicines at the same time.

It's important to talk to your doctor about which treatment options may be most appropriate for you.

SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

FOR USE WITH CirCLIQ™ On-Body Delivery System



Patient representation.


HOW SARCLISA ESCENA WORKS

SARCLISA ESCENA: Not chemotherapy. A targeted immunotherapy

Designed to **find and bind**

SARCLISA ESCENA is not chemotherapy. It is both a targeted therapy and an immunotherapy. As a targeted immunotherapy, SARCLISA ESCENA can "find and bind" to myeloma cells. It works with your immune system to help destroy myeloma cells.

SARCLISA ESCENA works in 3 distinct ways to reduce the number of myeloma cells in your body



SARCLISA ESCENA **finds and binds** to myeloma cells and exposes them for elimination by your immune system.

SARCLISA ESCENA helps **boost your immune system**, making it harder for myeloma cells to survive.

SARCLISA ESCENA **directly kills** myeloma cells.

Important Safety Information (cont'd)

How will I receive SARCLISA ESCENA?

- SARCLISA ESCENA will be given to you by your healthcare provider as an injection under the skin (subcutaneous injection) in the stomach area (abdomen). Your healthcare provider will either use the CirCLIQ™ On-Body Injector or a syringe to inject SARCLISA ESCENA. Your healthcare provider will rotate the injection site for each injection, including for other medicines.

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

FOR USE WITH CirCLIQ™ On-Body Delivery System

SARCLISA ESCENA™ for use with CirCLIQ™

SARCLISA ESCENA may be given using this unique device called CirCLIQ



Designed with you in mind

CirCLIQ is an on-body injector. It uses an adhesive to stick to your body while it delivers your medication under the skin as a subcutaneous injection.

SMALL, HIDDEN NEEDLE
CirCLIQ features a small, hidden, retractable needle that is smaller than standard injection needles. **You won't see the needle while the device is in use**

FLEXIBILITY TO MOVE AROUND
Once attached, CirCLIQ stays securely on your body. **This means during treatment you will have the flexibility to gently move around or talk to your nurse**

For administration by healthcare providers only.

When treatment with CirCLIQ is complete, your healthcare provider will remove the device from your body.

Important Safety Information (cont'd)

How will I receive SARCLISA ESCENA? (cont'd)

- **SARCLISA ESCENA in combination with pomalidomide and dexamethasone, or SARCLISA ESCENA in combination with carfilzomib and dexamethasone** is given in treatment cycles of 28 days (4 weeks).
  - Cycle 1 (28-day cycle), SARCLISA ESCENA is given weekly.
  - Cycle 2 and beyond (28-day cycles), SARCLISA ESCENA is given every 2 weeks.

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

About SARCLISA ESCENA

SARCLISA ESCENA is given by your healthcare provider as an injection under the skin (called a subcutaneous injection) in the stomach area. It may be given using the CirCLIQ on-body injector or a syringe.

SARCLISA ESCENA with **CirCLIQ**

The **only** multiple myeloma treatment given with an **on-body injector**

SARCLISA ESCENA with CirCLIQ was designed to transform the treatment experience for patients and providers.

See page 18 to learn how CirCLIQ works and what to expect during treatment.

SARCLISA ESCENA™ (isatuximab-irfc) Injection for subcutaneous use 1,400 mg/10 mL FOR USE WITH CirCLIQ™ On-Body Delivery System

SARCLISA ESCENA
FOR USE WITH CirCLIQ

CLINICAL TRIAL RESULTS

In a clinical trial, SARCLISA ESCENA™ had similar response rates to SARCLISA® (isatuximab-irfc)

SARCLISA ESCENA was studied in a clinical trial to determine whether it worked similarly to the FDA-approved medicine SARCLISA. **Both SARCLISA ESCENA and SARCLISA contain the same active ingredient**, which is isatuximab-irfc (pronounced ee-suh-TUK-si-mab).

SARCLISA ESCENA Trial 1: SARCLISA ESCENA + Pomalyst® (pomalidomide) and dexamethasone (Pd) vs SARCLISA + Pd

ABOUT THE TRIAL

This Phase 3 clinical trial included patients with previously treated multiple myeloma who had received at least 1 prior treatment, including Revlimid® (lenalidomide) and a proteasome inhibitor.

WHAT WAS MEASURED?

1. The percentage of patients whose multiple myeloma responded to treatment. **This is called the overall response rate.**

2. The amount of medicine in the bloodstream before the next dose. Medicine levels in your body decrease naturally over time. **Measuring this is a common way to confirm that an injection works similarly to an intravenous (or IV) infusion. This is called C_{trough} at steady state.**

WHO PARTICIPATED?

531 patients participated in the trial. Participants were randomly assigned to 1 of 2 treatment groups.

263 patients received **SARCLISA ESCENA + Pd**

268 patients received **SARCLISA + Pd**

FDA=Food and Drug Administration.

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

Adult patients with previously treated multiple myeloma who had taken SARCLISA ESCENA + Pd achieved similar response rates compared to patients who received SARCLISA® (isatuximab-irfc) + Pd

SARCLISA ESCENA TRIAL 1: RESULTS

Overall response rates

At 1 year (12 months)

SARCLISA ESCENA + Pd		SARCLISA + Pd
71.1%	vs	**70.5%**
187 out of 263 patients responded to treatment		189 out of 268 patients responded to treatment

WHAT DOES THIS MEAN?

Response rates for SARCLISA ESCENA were consistent with those of SARCLISA.

Want to learn more about the clinical trial results of SARCLISA?

Please see Important Safety Information for SARCLISA on page 29.

Scan here or visit SARCLISA.com

Important Safety Information (cont'd)

How will I receive SARCLISA ESCENA? (cont'd)

- **SARCLISA ESCENA in combination with bortezomib, lenalidomide, and dexamethasone** is given in treatment cycles of 28 days (4 weeks).
  - Cycle 1 (28-day cycle), SARCLISA ESCENA is given weekly.
  - Cycles 2 to 12 (28-day cycles), SARCLISA ESCENA is given every 2 weeks.
  - Cycles 13 and beyond, SARCLISA ESCENA is given every 4 weeks.

SARCLISA ESCENA™ (isatuximab-irfc) Injection for subcutaneous use 1,400 mg/10 mL FOR USE WITH CirCLIQ™ On-Body Delivery System

ADDITIONAL CLINICAL TRIALS

Across other combinations, a majority of patients responded to treatment with SARCLISA ESCENA™

Additional clinical trials studied how SARCLISA ESCENA performed in combination with other medicines in patients with previously treated multiple myeloma and in patients with newly diagnosed multiple myeloma who were not eligible for transplant.

SARCLISA ESCENA Trial 2: SARCLISA ESCENA + Velcade® (bortezomib), Revlimid® (lenalidomide), and dexamethasone (VRd)

ABOUT THE TRIAL

This Phase 2 clinical trial included patients with newly diagnosed multiple myeloma who were not eligible for autologous stem cell transplant (ASCT). The trial had 2 parts. First, patients started treatment with SARCLISA ESCENA + VRd. Then, patients continued treatment with SARCLISA ESCENA + Revlimid and dexamethasone (Rd) and stopped taking Velcade (V).

WHAT WAS MEASURED?

The trial measured **overall response rate**, or the percentage of patients who responded to treatment.

WHO PARTICIPATED?

74 patients participated in the trial. Everyone received the same treatment.

SARCLISA ESCENA TRIAL 2: RESULTS

Overall response rate for SARCLISA ESCENA + VRd



Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

SARCLISA ESCENA Trial 3: SARCLISA ESCENA + Kyprolis® (carfilzomib) and dexamethasone (Kd)

ABOUT THE TRIAL

This Phase 2 clinical trial included patients with previously treated multiple myeloma who had received 1 to 3 prior treatments.

WHAT WAS MEASURED?

The trial measured overall response rate, or the percentage of patients who responded to treatment.

WHO PARTICIPATED?

74 patients participated in the trial. Everyone received the same treatment.

SARCLISA ESCENA TRIAL 3 RESULTS

Overall response rate for SARCLISA ESCENA + Kd



WHAT DOES THIS MEAN?

Clinical trial results showed that a majority responded to treatment with SARCLISA ESCENA in combination with other medicines.

Important Safety Information (cont'd)

How will I receive SARCLISA ESCENA? (cont'd)

- Your healthcare provider will decide how many treatments you will receive.
- Your healthcare provider will give you medicines before each injection of SARCLISA ESCENA, to help reduce the risk and severity of allergic reactions, for at least Cycle 1 of treatment.
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

FOR USE WITH CirCLIQ™ On-Body Delivery System

Possible side effects of SARCLISA ESCENA™

Some people may experience a reaction to treatment with SARCLISA ESCENA. Make sure to notify your doctor of any pain or discomfort during or after treatment.

Allergic reactions

SARCLISA ESCENA can cause severe or life-threatening allergic reactions throughout the body (systemic administration reactions). Your healthcare provider may stop your injection and not complete it or completely stop treatment with SARCLISA ESCENA if you have an allergic reaction. Tell your healthcare provider or get medical help right away if you develop any of the following signs and symptoms of an allergic reaction including:

- shortness of breath, wheezing, or trouble breathing
- swelling of the face, mouth, throat, or tongue
- throat tightness
- heart beating faster than usual
- dizziness
- lightheadedness or fainting
- headache
- cough
- skin rash or itching
- nausea
- runny or stuffy nose
- chills

Injection site reactions

Injection site reactions can happen at or near the SARCLISA ESCENA injection site. Symptoms of these local skin reactions include redness, swelling, and pain. Tell your healthcare provider if you develop injection site reactions during treatment with SARCLISA ESCENA.

Decreased white blood cell counts

Decreased white blood cell counts are common and can be severe during treatment with SARCLISA ESCENA. If fever occurs, this may be a sign that you have an infection.

Your healthcare provider will check your blood cell counts during treatment with SARCLISA ESCENA and may prescribe medicine to help increase your white blood cell counts.

Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA ESCENA.

Infections

SARCLISA ESCENA can cause infections that are severe, life-threatening, or that can lead to death. Your healthcare provider will monitor you for signs and symptoms of infection before and during treatment with SARCLISA ESCENA. Your healthcare provider may prescribe medicines for you to help prevent infections and treat you as needed if you develop an infection during treatment with SARCLISA ESCENA.

Tell your healthcare provider right away if you develop a fever or any signs or symptoms of infection during treatment with SARCLISA ESCENA.

Risk of new cancers

New cancers have happened in people during treatment with SARCLISA ESCENA. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA ESCENA.

Changes in blood tests

SARCLISA ESCENA may affect the results of blood tests to match your blood type for at least 6 months after your last injection of SARCLISA ESCENA. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA ESCENA. **Tell all of your healthcare providers that you are being treated with SARCLISA ESCENA before receiving blood transfusions.**

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

Common side effects that may occur with SARCLISA ESCENA in combination with Pomalyst® and dexamethasone

- upper respiratory tract infection
- lung infection (pneumonia)
- tiredness
- muscle and joint pain
- diarrhea
- trouble sleeping
- COVID-19
- constipation
- swelling of the hands, legs, ankles, and feet

Common side effects that may occur with SARCLISA ESCENA in combination with Kyprolis® and dexamethasone

- upper respiratory tract infection
- muscle and joint pain
- lung infection (pneumonia)
- high blood pressure
- COVID-19
- trouble sleeping
- diarrhea
- fever

Common side effects that may occur with SARCLISA ESCENA in combination with Velcade®, Revlimid®, and dexamethasone

- tingling or numbness of the arms or legs
- constipation
- diarrhea
- tiredness
- muscle and joint pain
- upper respiratory tract infection
- reaction at the injection site
- trouble sleeping
- nausea and vomiting
- skin rash
- skin redness
- swelling throughout the body (edema)
- COVID-19
- back pain
- low blood pressure
- lung infection (pneumonia)
- bronchitis
- muscle spasm
- weight decreased
- flu
- urinary tract infection
- fever
- abdominal pain

Common abnormal blood test results that may occur during treatment with SARCLISA ESCENA combination therapies

- decreased white blood cell counts
- decreased red blood cell counts
- decreased platelet counts

Heart failure

Heart failure can happen during treatment with SARCLISA ESCENA in combination with carfilzomib and dexamethasone. **Tell your healthcare provider right away if you develop any of the following symptoms:**

- trouble breathing
- cough
- swelling of your ankles, feet, and legs

These are not all the possible side effects of SARCLISA ESCENA.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

FOR USE WITH CirCLIQ™ On-Body Delivery System



Patient representation.

Preparing for your treatment

Plan ahead to help make your experience more comfortable

Wear loose-fitting, comfortable clothing (other than dresses) that can be adjusted to expose your stomach, where the device will be placed.

Avoid using lotion on your stomach before injection as it can prevent CirCLIQ from sticking properly.

Take along a book, tablet, music, or anything that will help make your experience more enjoyable.

Discuss with your healthcare provider how long you should allow for your first appointment. Set aside enough time for premedications, injection, and any monitoring your healthcare provider may require afterwards.

Your healthcare provider will give you medicines before your SARCLISA ESCENA injections to help lower the chance of an allergic reaction during your first few injections. This may help make reactions less likely and severe.

Consider bringing this guide with you, along with a list of questions you may have for your care team.

Important Safety Information (cont'd)

What are the possible side effects of SARCLISA ESCENA?

SARCLISA ESCENA can cause serious side effects, including:

- **Allergic reactions.** SARCLISA ESCENA can cause severe or life-threatening allergic reactions throughout the body (systemic administration reactions). Your healthcare provider may stop your injection and not complete it or completely stop treatment with SARCLISA ESCENA if you have an allergic reaction. Tell your healthcare provider or get medical help right away if you develop any of the following signs and symptoms of an allergic reaction including:
  - shortness of breath, wheezing, or trouble breathing
  - swelling of the face, mouth, throat, or tongue
  - throat tightness
  - heart beating faster than usual
  - dizziness
  - lightheadedness or fainting
  - headache
  - cough
  - skin rash or itching
  - nausea
  - runny or stuffy nose
  - chills

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.


SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

FOR USE WITH CirCLIQ™ On-Body Delivery System

HOW CirCLIQ™ IS USED


What to expect during treatment

When you arrive for your appointment, your nurse will make sure the CirCLIQ device is filled, prepared, and ready.



They'll clean a small area on your stomach and gently place the device on your skin.


- The back of the device has a latex-free adhesive that helps it stay in place
- You won't get your treatment in the same place every time. Your care team will rotate the injection site with each treatment, including injections for other medicines



When it's time to begin, your nurse will press a button on the device.

- A small, hidden needle will enter your skin and start delivering your SARCLISA ESCENA™ dose automatically

The device delivers your treatment with the push of a button.
You can focus on whatever helps you feel comfortable and calm during treatment.



When the injection is complete, the needle retracts back into the device, and the button pops up.

- This lets your nurse know it's finished
- Your nurse will then remove the device and dispose of it safely

Your healthcare provider will discuss with you if they want you to remain in the clinic for monitoring.

A few helpful reminders

- Try not to bump or move the device while it's working
- Keep the area dry during the injection
- Tell your nurse if you have an acrylic allergy

Before you leave, make sure to schedule your next appointment.

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

FAQs

Your questions answered

Do I have to stay still during the entire injection?

No. One unique feature of the CirCLIQ device is that you do not have to stay still during treatment. Once the device is attached and starts to deliver medication, feel free to read, engage in light movement, or just relax.

How long does it take?

Talk with your healthcare provider about how much time to set aside for premedication, injection, and any monitoring required afterwards.

Can the CirCLIQ device be paused?

Yes, the device can be paused. If there is a need to stop it for any reason, your nurse can hold down the button to stop the flow of medicine. The needle will remain safely in place, and your nurse can resume it when you're ready.

How does SARCLISA ESCENA work to treat my multiple myeloma?

"How does SARCLISA ESCENA work?" is a great question, especially when you're managing several medications. SARCLISA ESCENA is not chemotherapy. It is a type of targeted immunotherapy that is able to "find and bind" to myeloma cells. SARCLISA ESCENA works together with your immune system to help destroy myeloma cells. Page 7 explains how SARCLISA ESCENA works in more detail.

Watch a video to better understand what to expect during your treatment and find other helpful resources.

Scan here or visit SARCLISA.com/resources

Important Safety Information (cont'd)

What are the possible side effects of SARCLISA ESCENA? (cont'd)

- **Injection site reactions** can happen at or near the SARCLISA ESCENA injection site. Symptoms of these local skin reactions include redness, swelling, and pain. Tell your healthcare provider if you develop injection site reactions during treatment with SARCLISA ESCENA.
- **Decreased white blood cell counts.** Decreased white blood cell counts are common and can be severe during treatment with SARCLISA ESCENA. If fever occurs, this may be a sign that you have an infection. Your healthcare provider will check your blood cell counts during treatment with SARCLISA ESCENA and may prescribe medicine to help increase your white blood cell counts. **Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA ESCENA.**

SARCLISA ESCENA™ (isatuximab-irfc) Injection for subcutaneous use 1,400 mg/10 mL FOR USE WITH CirCLIQ™ On-Body Delivery System


Treatment with SARCLISA ESCENA

Fewer injections after the first cycle

SARCLISA ESCENA is given by a healthcare provider as an injection under the skin in the stomach area (abdomen) with the CirCLIQ™ on-body injector or a syringe. Depending on where you are in your treatment journey with multiple myeloma, there are different treatment schedules for SARCLISA ESCENA.


Your SARCLISA ESCENA treatment schedule with Velcade® (bortezomib), Revlimid® (lenalidomide), and dexamethasone

For newly diagnosed non-transplant patients



Your SARCLISA ESCENA treatment schedule with Kyprolis® (carfilzomib) and dexamethasone or Pomalyst® (pomalidomide) and dexamethasone

For previously treated patients



Once prescribed, your doctor and other members of your care team will explain how you will receive SARCLISA ESCENA along with other medicines depending on your prescribed treatment regimen.

If you miss any appointments, call your healthcare provider as soon as possible to reschedule.

Important Safety Information (cont'd)

What are the possible side effects of SARCLISA ESCENA? (cont'd)

- **Infections.** SARCLISA ESCENA can cause infections that are severe, life-threatening, or that can lead to death. Your healthcare provider will monitor you for signs and symptoms of infection before and during treatment with SARCLISA ESCENA. Your healthcare provider may prescribe medicines for you to help prevent infections and treat you as needed if you develop an infection during treatment with SARCLISA ESCENA. **Tell your healthcare provider right away if you develop a fever or any signs or symptoms of infection during treatment with SARCLISA ESCENA.**
- **Risk of new cancers.** New cancers have happened in people during treatment with SARCLISA ESCENA. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA ESCENA.

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

SARCLISA ESCENA™ (isatuximab-irfc) Injection for subcutaneous use 1,400 mg/10 mL FOR USE WITH CirCLIQ™ On-Body Delivery System

careASSIST®
Sanofi Support

Sign up for support that's tailored to you

Once enrolled, you will receive free, personalized guidance and resources through the CareASSIST program

With you at every step

You'll be paired with a Case Manager who will get to know you. They'll help you:

- Navigate the insurance process
- Better understand your condition and treatment
- Connect with resources that provide emotional, logistical, and health-related support
- **Pay as little as $0*** out of pocket through the **CareASSIST Copay Program**, pending eligibility
- See if you qualify for the **CareASSIST Patient Assistance Program**, which allows you to receive your medication at no cost†
- Identify other financial assistance programs that may be able to help with treatment costs

***Important Notice: Subject to the program maximum per patient per calendar year.** Prescription must be for an approved indication. Not valid for prescriptions covered by or submitted for reimbursement, in whole or in part, under Medicare, Medicaid, VA, DoD, TRICARE®, or similar federal or state programs including any state pharmaceutical assistance programs. Not valid where prohibited by law. This offer is nontransferable, limited to one per person, and cannot be combined with any other offer or discount. Any savings provided by the program may vary depending on patients' out-of-pocket costs. Sanofi reserves the right to modify or discontinue the program at any time without notice. All program details provided upon registration.

†Free product is provided by Sanofi Cares North America (SCNA), a charitable organization of Sanofi under Section 501(c)(3) of the IRC.



Patient representation.

CareASSIST is here to help you!

If you have any questions or need assistance, reach out to a dedicated Case Manager at **1-833-WE+CARE (1-833-930-2273)**, Monday through Friday, 9 AM to 6 PM ET.

Enrolling in CareASSIST is easy, quick, and free

Scan the QR code to get started



Patient representation.

PATIENT AND CAREGIVER RESOURCES

Get information and helpful resources about SARCLISA ESCENA and multiple myeloma

Access additional patient and caregiver resources for SARCLISA ESCENA with CirCLIQ

Scan here or visit SARCLISA.com/resources

More helpful resources

Multiple myeloma information and support networks

These organizations and networks can offer helpful information about living with multiple myeloma. They can provide updates on the latest research about the disease and help connect you with emotional support resources, including others living with multiple myeloma.*

International Myeloma Foundation
myeloma.org | 800-452-2873

Multiple Myeloma Research Foundation
themmrf.org | 203-229-0464

Blood Cancer United
bloodcancerunited.org | 800-955-4572

HealthTree Foundation for Multiple Myeloma
healthtree.org/myeloma/community | 800-709-1113

*This listing is provided as a resource only and does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources on this topic may be available and should be investigated. Sanofi does not review or control the content of non-Sanofi websites. These listings do not constitute an endorsement by Sanofi of information provided by any other organizations.

Important Safety Information (cont'd)

What are the possible side effects of SARCLISA ESCENA? (cont'd)

- **Change in blood tests.** SARCLISA ESCENA may affect the results of blood tests to match your blood type for at least 6 months after your last injection of SARCLISA ESCENA. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA ESCENA. **Tell all of your healthcare providers that you are being treated with SARCLISA ESCENA before receiving blood transfusions.**

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL
FOR USE WITH CirCLIQ™ On-Body Delivery System

Glossary of terms

C_{trough}: The amount of medicine in the bloodstream just before the next dose. It is measured to help confirm that an injection works similarly to an infusion.

Immune system: The body's natural defense system against infections and diseases.

Intravenous (IV) infusion: A treatment given by needle or tube directly into a vein.

Overall response rate: A measure of how many patients saw their multiple myeloma respond to treatment. Response to treatment means the amount of abnormal protein made by the cancer (called M-protein) decreased, either partly or completely.

Refractory: When myeloma does not respond to treatment or stops responding to treatment.

Relapse: When the signs and symptoms of myeloma return after a period of improvement.

Transplant: Also referred to as an autologous stem cell transplant (ASCT), it is a procedure in which stem cells are removed from your body before chemotherapy treatment, and then returned afterward.

What is SARCLISA ESCENA?

SARCLISA ESCENA is a prescription medicine used in combination with:

- The medicines pomalidomide and dexamethasone, to treat adults who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
- The medicines carfilzomib and dexamethasone, to treat adults with multiple myeloma who have already received 1 to 3 lines of treatment, and they did not work or are no longer working.
- The medicines bortezomib, lenalidomide, and dexamethasone, to treat adults with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant).

It is not known if SARCLISA ESCENA is safe and effective in children.

Important Safety Information

Do not receive SARCLISA ESCENA if you have a severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA ESCENA (see the list of ingredients in the full Prescribing Information).

Before you receive SARCLISA ESCENA, tell your healthcare provider about all of your medical conditions, including if you:

- Have an infection.
- Have heart problems, if your healthcare provider prescribes SARCLISA ESCENA in combination with carfilzomib and dexamethasone for you.
- Have had shingles (herpes zoster).
- Are pregnant or plan to become pregnant. SARCLISA ESCENA can harm your unborn baby.

  Females who are able to become pregnant:
  - Your healthcare provider will check for pregnancy before you start treatment with SARCLISA ESCENA.
  - Use an effective birth control (contraception) during treatment and for 7 months after your last dose of SARCLISA ESCENA. Talk to your healthcare provider about birth control methods that you can use during this time.
  - Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with SARCLISA ESCENA.

  Females and males: Before receiving SARCLISA ESCENA in combination with either pomalidomide or lenalidomide, females and males must agree to the instructions in the pomalidomide or lenalidomide REMS programs. The pomalidomide and lenalidomide REMS programs have specific requirements about birth control, pregnancy testing, blood donation, and sperm donation that you need to know. Talk to your healthcare provider to learn more about pomalidomide or lenalidomide.
- Are breastfeeding or plan to breastfeed. It is not known if SARCLISA ESCENA passes into your breast milk. Do not breastfeed during treatment with SARCLISA ESCENA and for 7 months after your last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive SARCLISA ESCENA?

- SARCLISA ESCENA will be given to you by your healthcare provider as an injection under the skin (subcutaneous injection) in the stomach area (abdomen). Your healthcare provider will either use the CirCLIQ™ On-Body Injector or a syringe to inject SARCLISA ESCENA. Your healthcare provider will rotate the injection site for each injection, including for other medicines.
- **SARCLISA ESCENA in combination with pomalidomide and dexamethasone, or SARCLISA ESCENA in combination with carfilzomib and dexamethasone** is given in treatment cycles of 28 days (4 weeks).
  - Cycle 1 (28-day cycle), SARCLISA ESCENA is given weekly.
  - Cycle 2 and beyond (28-day cycles), SARCLISA ESCENA is given every 2 weeks.
- **SARCLISA ESCENA in combination with bortezomib, lenalidomide, and dexamethasone** is given in treatment cycles of 28 days (4 weeks).
  - Cycle 1 (28-day cycle), SARCLISA ESCENA is given weekly.
  - Cycles 2 to 12 (28-day cycles), SARCLISA ESCENA is given every 2 weeks.
  - Cycles 13 and beyond, SARCLISA ESCENA is given every 4 weeks.
- Your healthcare provider will decide how many treatments you will receive.
- Your healthcare provider will give you medicines before each injection of SARCLISA ESCENA, to help reduce the risk and severity of allergic reactions, for at least Cycle 1 of treatment.
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

What are the possible side effects of SARCLISA ESCENA?

SARCLISA ESCENA can cause serious side effects, including:

- **Allergic reactions.** SARCLISA ESCENA can cause severe or life-threatening allergic reactions throughout the body (systemic administration reactions). Your healthcare provider may stop your injection and not complete it or completely stop treatment with SARCLISA ESCENA if you have an allergic reaction. Tell your healthcare provider or get medical help right away if you develop any of the following signs and symptoms of an allergic reaction including:
  - shortness of breath, wheezing, or trouble breathing
  - swelling of the face, mouth, throat, or tongue
  - throat tightness
  - heart beating faster than usual
  - dizziness
  - lightheadedness or fainting
  - headache
  - cough
  - skin rash or itching
  - nausea
  - runny or stuffy nose
  - chills

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

SARCLISA ESCENA™ (isatuximab-irfc) Injection for subcutaneous use 1,400 mg/10 mL FOR USE WITH CirCLIQ™ On-Body Delivery System

Important Safety Information (cont'd)

- **Injection site reactions** can happen at or near the SARCLISA ESCENA injection site. Symptoms of these local skin reactions include redness, swelling, and pain. Tell your healthcare provider if you develop injection site reactions during treatment with SARCLISA ESCENA.
- **Decreased white blood cell counts.** Decreased white blood cell counts are common and can be severe during treatment with SARCLISA ESCENA. If fever occurs, this may be a sign that you have an infection. Your healthcare provider will check your blood cell counts during treatment with SARCLISA ESCENA and may prescribe medicine to help increase your white blood cell counts. **Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA ESCENA.**
- **Infections.** SARCLISA ESCENA can cause infections that are severe, life-threatening, or that can lead to death. Your healthcare provider will monitor you for signs and symptoms of infection before and during treatment with SARCLISA ESCENA. Your healthcare provider may prescribe medicines for you to help prevent infections and treat you as needed if you develop an infection during treatment with SARCLISA ESCENA. **Tell your healthcare provider right away if you develop a fever or any signs or symptoms of infection during treatment with SARCLISA ESCENA.**
- **Risk of new cancers.** New cancers have happened in people during treatment with SARCLISA ESCENA. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA ESCENA.
- **Change in blood tests.** SARCLISA ESCENA may affect the results of blood tests to match your blood type for at least 6 months after your last injection of SARCLISA ESCENA. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA ESCENA. **Tell all of your healthcare providers that you are being treated with SARCLISA ESCENA before receiving blood transfusions.**

The most common side effects of SARCLISA ESCENA in combination with pomalidomide and dexamethasone include:

- upper respiratory tract infection
- lung infection (pneumonia)
- tiredness
- muscle and joint pain
- diarrhea
- trouble sleeping
- COVID-19
- constipation
- swelling of the hands, legs, ankles, and feet

The most common side effects of SARCLISA ESCENA in combination with carfilzomib and dexamethasone include:

- upper respiratory tract infection
- muscle and joint pain
- lung infection (pneumonia)
- high blood pressure
- COVID-19
- trouble sleeping
- diarrhea
- fever

The most common side effects of SARCLISA ESCENA in combination with bortezomib, lenalidomide, and dexamethasone include:

- tingling or numbness of the arms or legs
- constipation
- diarrhea
- tiredness
- muscle and joint pain
- upper respiratory tract infection
- reaction at the injection site
- trouble sleeping
- nausea and vomiting
- skin rash
- skin redness
- swelling throughout the body (edema)
- COVID-19
- back pain
- low blood pressure
- lung infection (pneumonia)
- bronchitis
- muscle spasm
- weight decreased
- flu
- urinary tract infection
- fever
- abdominal pain

The most common abnormal blood test results during treatment with SARCLISA ESCENA combination therapies include:

- decreased white blood cell counts
- decreased red blood cell counts
- decreased platelet counts

Heart failure can happen during treatment with SARCLISA ESCENA in combination with carfilzomib and dexamethasone. **Tell your healthcare provider right away if you develop any of the following symptoms:**

- trouble breathing
- cough
- swelling of your ankles, feet, and legs

These are not all of the possible side effects of SARCLISA ESCENA. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information.

What is SARCLISA?

SARCLISA is a prescription medicine used in combination with:

- The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
- The medicines carfilzomib and dexamethasone, to treat adults with multiple myeloma who have already received 1 to 3 lines of treatment and they did not work or are no longer working.
- The medicines bortezomib, lenalidomide and dexamethasone, to treat adults with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant).

It is not known if SARCLISA is safe and effective in children.

Important Safety Information

Do not receive SARCLISA if you have a severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA (see the list of ingredients in the full Prescribing Information).

Before receiving SARCLISA, tell your healthcare provider about all of your medical conditions, including if you:

- Have an infection.
- Have heart problems, if your healthcare provider prescribes SARCLISA in combination with carfilzomib and dexamethasone for you.
- Have had shingles (herpes zoster).
- Are pregnant or plan to become pregnant. SARCLISA can harm your unborn baby.
  - Females who are able to become pregnant should use an effective method of birth control during treatment and for 5 months after your last dose of SARCLISA. Talk to your healthcare provider about birth control methods that you can use during this time.
  - Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with SARCLISA.
  - Before receiving SARCLISA in combination with either pomalidomide or lenalidomide, females and males must agree to the instructions in the pomalidomide or lenalidomide REMS program. The pomalidomide and lenalidomide REMS program have specific requirements about birth control, pregnancy testing, blood donation, and sperm donation that you need to know. Talk to your healthcare provider to learn more about pomalidomide or lenalidomide.

SARCLISA® (isatuximab-irfc)
Injection for intravenous use
500 mg/25 mL, 100 mg/5 mL

SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

FOR USE WITH CirCLIQ™ On-Body Delivery System

Important Safety Information (cont'd)

- Are breastfeeding or plan to breastfeed. It is not known if SARCLISA passes into your breast milk. Do not breastfeed during treatment with SARCLISA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive SARCLISA?

- SARCLISA will be given to you by your healthcare provider by intravenous (IV) infusion into your vein.
- **SARCLISA in combination with pomalidomide and dexamethasone, or SARCLISA in combination with carfilzomib and dexamethasone** is given in treatment cycles of 28 days (4 weeks).
  - Cycle 1 (28-day cycle), SARCLISA is given weekly.
  - Cycle 2 and beyond (28-day cycles), SARCLISA is given every 2 weeks.
- **SARCLISA in combination with bortezomib, lenalidomide, and dexamethasone** is given in treatment cycles of 42 days (6 weeks) from cycle 1 to 4 and in treatment cycles of 28 days (4 weeks) from cycle 5.
  - Cycle 1 (42-day cycle), SARCLISA is given weekly (Days 1, 8, 15, 22, and 29).
  - Cycles 2 to 4 (42-day cycles), SARCLISA is given every 2 weeks (Days 1, 15, and 29).
  - Cycles 5 to 17 (28-day cycles), SARCLISA is given every 2 weeks (Days 1 and 15).
  - Cycles 18 and beyond (28-day cycles), SARCLISA is given every 4 weeks.
- Your healthcare provider will decide how many treatments you will receive.
- Your healthcare provider will give you medicines before each infusion of SARCLISA to help reduce the risk of infusion reactions (make them less frequent and severe).
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

What are the possible side effects of SARCLISA?

SARCLISA may cause serious side effects, including:

- **Infusion reactions.** Infusion reactions are common with SARCLISA and can sometimes be severe or life threatening.
  - Your healthcare provider will prescribe medicines before each infusion of SARCLISA to help decrease your risk for infusion reactions or to help make any infusion reaction less severe. You will be monitored for infusion reactions during each infusion of SARCLISA.
  - Your healthcare provider may slow down or stop your infusion, or completely stop treatment with SARCLISA if you have an infusion reaction.

Get medical help right away if you develop any of the following symptoms of infusion reaction during or after an infusion of SARCLISA:

- shortness of breath, wheezing, or trouble breathing
- swelling of the face, mouth, throat, or tongue
- throat tightness
- palpitations
- dizziness, lightheadedness, or fainting
- headache
- cough
- rash or itching
- nausea
- runny or stuffy nose
- chills

- **Infections.** SARCLISA can cause infections that are severe, life-threatening, or that may lead to death. Your healthcare provider will monitor you for signs and symptoms of infection before and during treatment with SARCLISA. Your healthcare provider may prescribe medicines for you to help prevent infections and treat you as needed if you develop an infection during treatment with SARCLISA. **Tell your healthcare provider right away if you develop a fever or any signs or symptoms of infection during treatment with SARCLISA.**

  - **Decreased white blood cell counts.** Decreased white blood cell counts are common with SARCLISA and certain white blood cells can be severely decreased. Fever can occur with low white blood cell counts and may be a sign that you have an infection. Your healthcare provider will check your blood cell counts during treatment with SARCLISA and may prescribe a medicine to help increase your white blood cell counts. **Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA.**
- **Risk of new cancers.** New cancers have happened in people during and after treatment with SARCLISA. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA.
- **Change in blood tests.** SARCLISA may affect the results of blood tests to match your blood type for about 6 months after your last infusion of SARCLISA. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA. **Tell all of your healthcare providers that you are being treated with SARCLISA before receiving blood transfusions.**

The most common side effects of SARCLISA in combination with pomalidomide and dexamethasone include:

- upper respiratory tract infection
- lung infection (pneumonia)
- diarrhea
- decreased red blood cell count (anemia)
- decreased platelet count (thrombocytopenia)

The most common side effects of SARCLISA in combination with carfilzomib and dexamethasone include:

- upper respiratory tract infection
- tiredness and weakness
- high blood pressure
- diarrhea
- lung infection (pneumonia)
- trouble breathing
- trouble sleeping
- bronchitis
- cough
- back pain
- decreased red blood cell count (anemia)
- decreased platelet count (thrombocytopenia)

The most common side effects of SARCLISA in combination with bortezomib, lenalidomide and dexamethasone include:

- upper respiratory tract infection
- diarrhea
- tiredness and weakness
- tingling or numbness of the arms or legs
- lung infection (pneumonia)
- muscle or bone pain
- clouding of your eye (cataract)
- constipation
- swelling of the hands, legs, ankles and feet
- rash
- trouble sleeping
- COVID-19
- decreased red blood cell count (anemia)
- decreased platelet count (thrombocytopenia)

Heart failure can happen during treatment with SARCLISA in combination with carfilzomib and dexamethasone. **Tell your healthcare provider right away if you develop any of the following symptoms:**

- trouble breathing
- cough
- swelling of your ankles, feet, or legs

These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider or pharmacist.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information.

SARCLISA® (isatuximab-irfc)
Injection for intravenous use
500 mg/25 mL, 100 mg/5 mL

SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL
FOR USE WITH CirCLIQ™ On-Body Delivery System

SARCLISA ESCENA WITH CirCLIQ™

TRANSFORM THE SUBCUTANEOUS TREATMENT EXPERIENCE

The only multiple myeloma therapy given with an on-body injector

Designed with you in mind

- Small, hidden needle
- Flexibility to move around during treatment
- Treatment delivered with the push of a button



Scan here or visit SARCLISA.com/resources to learn more about SARCLISA ESCENA with CirCLIQ

For administration by healthcare providers only.

Ask your doctor if on-body delivery with SARCLISA ESCENA with CirCLIQ is right for you

What is SARCLISA ESCENA?

SARCLISA ESCENA is a prescription medicine used in combination with:

- The medicines pomalidomide and dexamethasone, to treat adults who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
- The medicines carfilzomib and dexamethasone, to treat adults with multiple myeloma who have already received 1 to 3 lines of treatment, and they did not work or are no longer working.
- The medicines bortezomib, lenalidomide, and dexamethasone, to treat adults with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant).

It is not known if SARCLISA ESCENA is safe and effective in children.

Important Safety Information

Do not receive SARCLISA ESCENA if you have a severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA ESCENA (see the list of ingredients in the full Prescribing Information).

Please see additional Important Safety Information throughout, and full Prescribing Information, including Patient Information.

SARCLISA ESCENA™ (isatuximab-irfc)
Injection for subcutaneous use
1,400 mg/10 mL

FOR USE WITH CirCLIQ™ On-Body Delivery System

sanofi

©2026 Sanofi. All rights reserved. SARCLISA, CareASSIST, and Sanofi are registered trademarks of Sanofi or an affiliate. SARCLISA ESCENA and CirCLIQ are trademarks of Sanofi or an affiliate. All the other trademarks above are the property of their respective owners, who have no affiliation or relationship with Sanofi. MAT-US-2601643-v1.0-07/2026